<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1505233646
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Oncaspar
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PEGASPARGASE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        750
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        8368.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LES LABORATOIRES SERVIER INDUSTRIE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LES LABORATOIRES SERVIER INDUSTRIE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 4377]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Servier Saudi Arabia Trading LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LES LABORATOIRES SERVIER 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX24
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Oncaspar contains pegaspargase, which is an enzyme (asparaginase) that breaks down asparagine, an important building block of proteins without which cells cannot survive. Normal cells can make asparagine for themselves, while some cancer cells cannot. Oncaspar lowers asparagine level in blood cancer cells and stops the cancer cells growing.</p><p>Oncaspar is used to treat acute lymphoblastic leukaemia (ALL) in children from birth to 18 years and in adults. ALL is a white blood cell cancer type in which certain immature white cells (named lymphoblasts) start growing out of control thus preventing the production of functional blood cells. Oncaspar is used together with other medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Oncaspar: </strong></p><p>- if you are allergic to pegaspargase or to any of the other ingredients of this medicine (listed in section 6).</p><p>- if you have severe hepatic disease.</p><p>- if you have ever had pancreatitis.</p><p>- if you have ever had severe bleeding following asparaginase therapy.</p><p>- if you have ever had blood clots following asparaginase therapy.</p><p>&nbsp;</p><p>Tell your doctor if any of these conditions apply to you. If you are the parent of a child who is being treated with Oncaspar, please tell the doctor if any of them apply to your child.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor before you are given Oncaspar. This medicine may not be suitable for you:</p><p>- if you have had serious allergic reactions to other forms of asparaginase, for example itching, flushing or swelling of the airways, because major allergic reactions to Oncaspar can occur.</p><p>- if you suffer from a bleeding disorder or have had serious blood clots.</p><p>- if you get a fever. This medicine may make you more susceptible to infections.</p><p>&nbsp;</p><p>&nbsp;</p><p>- if you have had poor liver function or are using other medicines which may harm the liver. When Oncaspar is used in combination with other cancer treatments, liver and central nervous system damage can occur.</p><p>- if you suffer abdominal pain. Inflammation of the pancreas, that in some cases caused death, can occur with Oncaspar treatment.</p><p>&nbsp;</p><p>This medicine can lead to fluctuations in clotting factors and may increase the risk of bleeding and/or clotting.</p><p>A side effect called osteonecrosis (bone damage) has been reported in the post-marketing setting in children and adolescents receiving Oncaspar (higher incidence seen in girls), when taken concomitantly with glucocorticoids (e.g. dexamethasone).</p><p>&nbsp;</p><p>If you are the parent of a child being treated with Oncaspar, tell the doctor if any of the above conditions apply to your child.</p><p><strong>During treatment with Oncaspar </strong></p><p>During Oncaspar administration you will be closely watched for an hour after the start of treatment for any signs of serious allergic reactions. Medical equipment to treat allergic reactions will be available nearby.</p><p>Additional monitoring tests</p><p>Blood and urine sugar levels, liver and pancreas function and other tests will be carried out regularly to monitor your health during and after treatment because this medicine can affect your blood and other organs.</p><p><strong>Other medicines and Oncaspar </strong></p><p>Tell your doctor if you are using, have recently used or might use any other medicines. This is important as Oncaspar may increase the side effects of other medicines through its effect on the liver which plays an important role in removing medicines from the body. In addition, it is especially important to tell your doctor if you are also using any of the following medicines:</p><p>- immunisation with live vaccines within three months of completing your leukaemia treatment. This will increase the risk of severe infections.</p><p>- vincristine, another cancer medicine. If used at the same time as Oncaspar there is an increased risk of side effects or allergic reactions.</p><p>- medicines which reduce the blood&acute;s ability to clot such as anticoagulants (e.g., coumarin/warfarin and heparin), dipyridamol, acetylsalicylic acid or non-steroidal anti-inflammatory medicines (such as ibuprofen or naproxen). If used at the same time as Oncaspar, there is a higher risk of bleeding disorders.</p><p>- medicines which require cell division for their effect, for example, methotrexate (a medicine used for cancer as well as arthritis treatment) may have a decrease in its effect.</p><p>- prednisone, a steroid medicine. If used at the same time as Oncaspar, the effects on the clotting ability of your blood are increased.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glucocorticoids when taken at the same time as part of recommended leukamia treatment, Oncaspar may increase the risk of steroid-induced osteonecrosis (bone damage) in children and adolescents, with a higher incidence seen in girls. Therefore, if you experience any new bone pain (i.e. pain in hip, knee or back), please inform your doctor as soon as possible.</p><p>- cytarabine, a medicine which can be used in cancer treatment, and could interfere with the effects of Oncaspar.</p><p>&nbsp;</p><p>Oncaspar can also cause changes in liver function which can affect the way other medicines work.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p>You should not use Oncaspar if you are pregnant because its effects during pregnancy have not been studied. Your physician will decide whether your disease requires treatment. Women who are able to get pregnant must use reliable contraception during treatment, and for at least 6 months after Oncaspar treatment has been discontinued. Oral contraception is not an effective method of contraception while on treatment with Oncaspar. Ask your doctor for advice on the best contraceptive method that you can use. Men must also use effective contraception while they or their partners are being treated with Oncaspar.</p><p>&nbsp;</p><p>It is not known whether pegaspargase is excreted inbreast milk. As a precautionary measure, breast-feeding should be discontinued during treatment with Oncaspar and should not be re-started until after treatment with Oncaspar has been discontinued.</p><p><strong>Driving and using machines </strong></p><p>Do not drive or use machines when using this medicine because it may make you feel drowsy, tired or confused.</p><p><strong>Oncaspar contains sodium </strong></p><p>This medicine contains less than 1 mmol sodium per dose, that is to say essentially &acute;sodium-free&acute;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Before administration, you might receive combination of medicines to help reduce your chances of getting allergic reactions. Your doctor will decide whether such premedication is necessary.</p><p>&nbsp;</p><p>Your treatment with Oncaspar has been prescribed by a doctor experienced in medicines used to treat cancer. Your doctor will decide what dose of the medicine is needed and how often, based on your age and body surface area which is calculated from your height and weight.</p><p>The medicine is given as a solution by injection into a muscle or, if more suitable, into a vein.</p><p><strong>If you are given too much Oncaspar </strong></p><p>As your doctor will administer the medicine, it is very unlikely you will be given more than you need.</p><p>In the unlikely event of accidental overdose, you will be monitored carefully by medical staff and treated appropriately.</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Serious side effects </strong></p><p>Tell your doctor <strong>immediately </strong>if you get any of the following side effects:</p><p><strong>Very common (may affect more than 1 in 10 people) </strong></p><p>- Inflammation or other disorders of the pancreas (pancreatitis) causing severe stomach pain which may spread to your back, vomiting, increase in blood sugar levels;</p><p>- Serious allergic reactions with symptoms such as rash, itching, swelling, hives, shortness of breath, fast heart beat and drop in blood pressure;</p><p>- Blood clots;</p><p>- Fever with low counts of white blood cells.</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people) </strong></p><p>- Severe bleeding or bruising;</p><p>- Violent shaking (seizures) and loss of consciousness;</p><p>- Severe infection with very high fever;</p><p>- Problems with your liver (e.g., change in colour of your skin or urine or stool and laboratory results of elevated liver enzymes or bilirubin).</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people) </strong></p><p>- Liver failure;</p><p>- Jaundice;</p><p>- Blocked bile flow from the liver (cholestasis);</p><p>- Destruction of liver cells (liver cell necrosis).</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data) </strong></p><p>- Severe skin reaction called toxic epidermal necrolysis;</p><p>- Loss of kidney function (e.g., change in urine output, swelling of feet and ankles);</p><p>- Stroke;</p><p>- Severe allergic reaction that may cause loss of consciousness and could be life-threatening (anaphylactic shock).</p><p>-&nbsp;Bone damage (osteonecrosis).</p><p>&nbsp;</p><p><strong>Other side effects </strong></p><p>Talk to your doctor if you get any of the following:</p><p><strong>Very common (may affect more than 1 in 10 people) </strong></p><p>- Changes in the function of the pancreas;</p><p>- Weight loss;</p><p>- Leg pain (which could be a symptom of thrombosis), chest pain or shortness of breath (which may be a symptom of blood clots in the lungs, called pulmonary embolism);</p><p>- Loss of appetite, general weakness, vomiting, diarrhoea, nausea;</p><p>- Increased blood sugar levels.</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people) </strong></p><p>- Decreased number of red blood cells;</p><p>- Build-up of fluid in the stomach (ascites);</p><p>- Fever and flu-like symptoms;</p><p>- Mouth sores;</p><p>- Back, joint or abdominal pain;</p><p>- High levels of fat and cholesterol in your blood; low potassium in your blood.</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people) </strong></p><p>- Reversible posterior leukoencephalopathy syndrome (RPLS), a syndrome characterised by headache, confusion, seizures and visual loss which resolves after some time.</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data) </strong></p><p>- Decreased number of white blood cells and platelets;</p><p>- Fever;</p><p>- Cysts in your pancreas, swelling of the salivary glands;</p><p>- High levels of urea in your blood; antibodies against Oncaspar; high levels of ammonia in your blood; decreased blood sugar levels;</p><p>- Sleepiness, confusion, mild twitching of the fingers.</p><p>&nbsp;</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects you think might be related to your chemotherapy , talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2&deg;C&ndash;8&deg;C).</p><p>Do not freeze.</p><p>&nbsp;</p><p>After the medicine has been reconstituted and diluted, the solution should be used immediately. If immediate use is not possible, the diluted solution can be stored at 2&deg;C-8&deg;C for up to 48 hours.</p><p>Do not use this medicine if you notice the reconstituted solution is cloudy or has visible particles.</p><p>Do not throw away any medicines via wastewater. Ask the pharmacist how to dispose of unused medicines. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is pegaspargase. Each vial contains 3,750 U of pegaspargase.</p><p>After reconstitution, 1 ml of solution contains 750 U pegaspargase (750 U/ml).</p><p>The other ingredients are: disodium phosphate heptahydrate, sodium dihydrogen phosphate monohydrate, sodium chloride, sucrose, sodium hydroxide (for pH adjustment), hydrochloric acid (for pH adjustment) (see section 2 &ldquo;Oncaspar contains sodium&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Oncaspar is a white to off-white powder. After reconstitution, the solution is clear, colourless and free from visible foreign particles. 
Each pack contains 1 glass vial with 3,750 U pegaspargase. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Les Laboratoires Servier</p><p>50, rue Carnot</p><p>92284 Suresnes cedex</p><p>France</p><p><strong>Manufacturer </strong></p><p>Les Laboratoires Servier Industrie</p><p>905 Route de Saran</p><p>45520 Gidy</p><p>France</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Saudi Arabia </strong></p><p>Servier Saudi Arabia Scientific Office</p><p>3533 Al Hawiy - Hitteen Dist.</p><p>1st floor - Office #101</p><p>Kingdom of Saudi Arabia</p><p>Tel.: +966 011 252 2330</p><p>E-mail: regulatory.sa1@servier.com</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Gulf Countries</strong></p><p>Les Laboratoires Servier Scientific Office</p><p>P.O. Box 1586, Level 15, Arenco Tower,&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dubai Media city, Sheikh Zayed Road,</p><p>Dubai, UAE</p><p>Tel: +971 4 3329903</p><p>E-mail: magdy.abdou@ servier.com</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 
07/2022 

To report any side effect(s):

•	Saudi Arabia:

- National Pharmacovigilance Center (NPC)
- SFDA call Center 19999
- E-mail: npc.drug@sfda.gov.sa
- Website: https://ade.sfda.gov.sa/

•	Other GCC states:

- Please contact the relevant competent authority.

f. Council of Arab Health Ministers:


This is a Medicament

- Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
- Follow the doctor's prescription, the method of use and the instruction of the pharmacist who sold the medicament.
- The doctor and the pharmacist are the experts in medicines, their benefits and risks.
- Do not by yourselves interrupt the period of treatment prescribed for you.
- Do not repeat the same prescription without consulting your doctor.
- Keep all medicaments out of reach of children

Council of Arab Health Ministers
		Union of Arab Pharmacists

g. This patient information leaflet is approved by the Saudi Food and Drug Authority 
--------------------------------------------------------------------------------------------------------------------------- 
The following information is intended for healthcare professionals only: 
It is strongly recommended that every time Oncaspar is administered to a patient, the name and lot number of the product are recorded in order to link the patient and the lot of the product. 
In view of the unpredictability of adverse reactions, Oncaspar should be administered only by health care personnel experienced in the use of cancer chemotherapeutic medicinal products. 
Particularly in patients with known hypersensitivity to the other forms of L-asparaginase, hypersensitivity reactions to Oncaspar can occur during the therapy, e.g., anaphylaxis. A routine precaution is to observe the patients for an hour with resuscitation equipment and other items required for the treatment of anaphylaxis in readiness (epinephrine, oxygen, intravenous steroids etc.). 
Patients should be informed about possible hypersensitivity reactions to Oncaspar, including immediate anaphylaxis. Patients who receive Oncaspar are at increased risk of bleeding and 

thrombotic disorders. It should be explained to patients that Oncaspar should not be used at the same time as other medicines associated with an increased risk of bleeding (see section 2 “Other medicines and Oncaspar”). 
This medicinal product can cause irritation on contact. The powder must therefore be handled and administered with particular care. Inhalation of the vapour and contact with the skin and mucosa, particularly that of the eyes, must be avoided; if the product comes in contact with eyes, skin, or mucous membranes, rinse immediately with plenty of water for at least 15 minutes. 
Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 
Instructions on how to prepare, store and dispose of Oncaspar 
Instructions for handling 
1. Staff should be trained in how to handle and transfer the medicinal product (pregnant staff should be excluded from working with this medicinal product). 
2. Aseptic technique must be used. 
3. Procedures for proper handling of antineoplastic agents should be observed. 
4. The use of disposable gloves and protective garments is recommended when handling Oncaspar. 
5. All items for administration or cleaning, including gloves, should be placed in high-risk waste disposal bags for high-temperature incineration. 

Reconstitution 
1. 5.2 ml water for injections are injected into the vial using a syringe and 21 gauge needle. 
2. The vial should be gently swirled until the powder is reconstituted. 
3. After reconstitution, the solution should be clear, colourless and free from visible foreign particles. Do not use if the reconstituted solution is cloudy or if a precipitate has formed. Do not shake. 
4. The solution should be used within 24 hours after reconstitution, when stored below 25°C. 

Administration 
1. Parenteral medicinal products should be inspected for particulate matter prior to administration, only a clear, colourless solution free from visible foreign particles should be used. 
2. The medicinal product should be administered intravenously or intramuscularly. The solution should be administered slowly. 

For intramuscular injection, the volume should not exceed 2 ml in children and adolescents and 3 ml in adults. 
For intravenous administration, the reconstituted solution should be diluted in 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution. 
The diluted solution can be given over 1 to 2 hours together with an already-running infusion of either sodium chloride 9 mg/ml (0.9%) solution or 5% glucose. Do not infuse other medicinal products through the same intravenous line during administration of Oncaspar. 
After dilution, the solution should be used immediately. If immediate use is not possible, the diluted solution can be stored at 2°C-8°C for up to 48 hours. 
Disposal 
Oncaspar is for single use only. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 
Further detailed information can be found in the SmPC.


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي أونكاسبار على بيغاسبارغاس، وهو إنزيم (اسباراجيناز) يعمل على تفكيك الأسباراجين، المادة الأساسية لبناء البروتينات التي لا تستطيع الخلية الاستمرار في الحياة من دونها. تستطيع الخلايا الطبيعية أن تشكّل الأسباراجين لوحدها، بينما لا تتمكن بعض الخلايا السرطانية من ذلك. يُنقص أونكاسبار معدّل الأسباراجين في خلايا سرطان الدم ويوقف نمو الخلايا السرطانية.</p><p>&nbsp;</p><p dir="RTL">يستعمل أونكاسبار لعلاج لوكيميا الأرومات اللمفاوية الحاد (ALL) لدى الأطفال منذ الولادة وحتى سن الثامنة عشرة ولدى البالغين. لوكيميا الأرومات اللمفاوية الحاد هو نوع من أنواع سرطان خلايا الدم البيضاء حيث يبدأ نوع معين من خلايا الدم البيضاء غير الناضجة (وتدعى الأرومات اللمفاوية) بالنمو بطريقة خارجة عن السيطرة ويمنع بالتالي إنتاج خلايا الدم الوظيفية. يستعمل أونكاسبار مع أدوية أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL"><strong>لا تستعمل أونكاسبار:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بالحساسية تجاه بيغاسبارغاس أو أي من مكونات هذا الدواء الأخرى (المذكورة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بمرض كبدي شديد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن أصبت بالتهاب البنكرياس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن أصبت بنزف شديد بعد العلاج بواسطة أسباراجيناز.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن أصبت بخثرات دموية بعد العلاج بواسطة أسباراجيناز.</p><p>&nbsp;</p><p dir="RTL">إذا أصبت بأي من هذه الحالات فيجب أن تبلغ طبيبك على الفور. إذا كنت أحد والدي الطفل الذي يعالج بواسطة أونكاسبار، فالرجاء إبلاغ الطبيب إذا كان أي من تلك الحالات ينطبق على طفلك.</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدّث مع طبيبك قبل أن تُعطى أونكاسبار. قد يكون هذا الدواء غير مناسب لك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بتفاعلات تحسسية تحاه الأشكال الأخرى من أسباراجيناز، مثل الحكة، التبيّغ أو تورم الممرات الهوائية، نظرا لإمكانية حدوث تفاعلات تحسسية شديدة تجاه أونكاسبار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب نزفي أو إذا سبق وأن أصبت بخثرات دموية خطيرة.&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بحمى (ارتفاع الحرارة). قد يجعلك هذا الدواء أكثر عرضة للإصابة بالعدوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من سوء الوظيفة الكبدية أو إذا كنت تستعمل أدوية أخرى قد تؤذي الكبد. عندما يستعمل أونكاسبار مع علاجات السرطان الأخرى، قد يتعرض الكبد والجهاز العصبي المركزي للضرر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ألم في البطن. قد يحدث التهاب البنكرياس، الذي يسبب الموت في بعض الأحيان، مع العلاج بواسطة أونكاسبار.</p><p>&nbsp;</p><p dir="RTL">قد يسبب هذا الدواء تبدلا في معدّلات عوامل التخثر وقد يزيد من إمكانية حدوث النزف و/أو التخثّر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن تأثير جانبي يسمى تنخر العظم (تلف العظام) في بيئة ما بعد التسويق لدى الأطفال والمراهقين الذين يتلقون أونكاسبار Oncaspar (نسبة حدوث أعلى عند الفتيات)، عند تناوله بشكل متزامن مع الجلوكورتيكويدات (مثل ديكساميثازون).</p><p>&nbsp;</p><p dir="RTL">إذا كنت أحد والدي الطفل الذي يعالج بواسطة أونكاسبار، فالرجاء إبلاغ الطبيب إذا كان أي من الحالات المذكورة أعلاه ينطبق على طفلك.</p><p>&nbsp;</p><p dir="RTL"><strong>أثناء العلاج بواسطة أونكاسبار</strong></p><p dir="RTL">في أثناء إعطائك أونكاسبار، ستوضع تحت مراقبة دقيقة لمدة ساعة بعد بدء العلاج تحسبا لظهور أي علامة للتفاعلات التحسسية الخطيرة. ستكون المعدات الطبية اللازمة لعلاج التفاعلات التحسسية متوفرة وقريبة.</p><p>&nbsp;</p><p dir="RTL"><u>اختبارات المراقبة الإضافية</u></p><p dir="RTL">ستُجرى اختبارات معدلات السكر في الدم والبول، الوظيفة الكبدية والبنكرياسية وسواها من الاختبارات بشكل منتظم لمراقبة حالتك الصحية في أثناء العلاج وبعده لأن هذا الدواء قد يؤثر على دمك وأعضاء جسمك الأخرى.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وأونكاسبار</strong></p><p dir="RTL">أعلم طبيبك إذا كنت تتناول حالياً، تناولت مؤخّراً أو قد تتناول أي دواء آخر. هذا الأمر مهم جدا لأن أونكاسبار قد يزيد من إمكانية حدوث التأثيرات الجانبية الناجمة عن الأدوية الأخرى بسبب تأثيره على الكبد الذي يلعب دورا هاما في تخليص الجسم من الأدوية. بالإضافة إلى ذلك، من المهم بشكل خاص أن تخبر طبيبك إذا كنت تستعمل أيا من الادوية التالية:&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التمنيع (اللقاحات) بواسطة لقاحات حيّة خلال ثلاثة شهور من إنهاء علاج اللوكيميا. فهذا سيزيد من إمكانية حدوث حالات العدوى الخطيرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فنكرستين، دواء آخر لعلاج السرطان. إذا استعمل في نفس وقت استعمال أونكاسبار، تزداد إمكانية حدوث التأثيرات الجانبية أو التفاعلات التحسسية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تنقص قابلية الدم على التخثّر مثل مضادات التخثّر (على سبيل المثال، الكومارين/ الوارفرين والهيبارين)، ديبيريدامول، حمض الأستيل ساليسيليك أو مضادات الالتهاب غير الستيرويدية (مثل ايبوبروفين أو نابروكسين). إذا استُعملت في نفس وقت استعمال أونكاسبار، تزداد إمكانية حدوث الاضطرابات النزفية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تتطلب انقسام الخلايا لكي تؤثّر، مثلا، ميثوتريكسات (دواء يستعمل لعلاج السرطان بالإضافة إلى علاج التهاب المفاصل) قد يبدي تناقصا في تأثيره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البردنيزولون، دواء ستيرويدي. إذا استعمل في نفس وقت استعمال أونكاسبار، فإن تأثيراته على قابلية دمك للتخثّر تزداد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - عند تناول الجلوكوكورتيكويد في نفس الوقت في إطار علاج موصى به لسرطان الدم ، قد يزيد أونكاسبار Oncaspar من خطر الإصابة بالنخر العظمي الناجم عن الستيرويد (تلف العظام) لدى الأطفال والمراهقين، مع حدوث نسبة أعلى عند الفتيات. وبالتالي، إذا كنت تعاني من أي ألم جديد في العظام (أي ألم في الورك أو الركبة أو الظهر) ، فيرجى إبلاغ طبيبك في أقرب وقت ممكن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتارابين، دواء يمكن أن يستعمل في علاج السرطان، وقد يتداخل في تأثيرات أونكاسبار.</p><p>&nbsp;</p><p dir="RTL">كما يمكن أن يسبب أونكاسبار تغيرات في الوظيفة الكبدية قد تؤثر على طريقة عمل الأدوية الأخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع </strong></p><p dir="RTL">إذا كنت حاملا أو مرضعا، أو تعتقدين بأنك حامل أو تخططين للإنجاب، فاطلبي نصيحة طبيبك قبل استعمال هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">يجب أن تمتنعي عن استخدام أونكاسبار إذا كنت حاملا لأن تأثيراته أثناء الحمل لم تدرس. سيقرر طبيبك ما إذا كان مرضك يتطلب علاجا. يجب أن تستعمل السيدات القادرات على الحمل وسيلة فعالة لمنع الحمل أثناء العلاج، ولمدة 6 أشهر على الأقل بعد التوقف عن العلاج بواسطة أونكاسبار. أقراص منع الحمل المتناولة عن طريق الفم ليست وسيلة فعالة أثناء العلاج بواسطة أونكاسبار. اطلبي نصيحة طبيبك بشأن افضل طريقة يمكنك استعمالها لمنع الحمل. كما يجب أن يستعمل الرجال أيضا وسيلة فعالة لمنع الحمل في أثناء علاجهم أو علاج شريكاتهم بواسطة أونكاسبار.</p><p>&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان بيغاسبارغاس ينتقل إلى حليب الثدي. كإجراء وقائي، يجب التوقف عن الإرضاع الطبيعي في أثناء العلاج بواسطة أونكاسبار ويجب عدم بدئه مجددا إلى ما بعد التوقف عن العلاج بواسطة أونكاسبار.</p><p>&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستعمال الآليات</strong></p><p dir="RTL">امتنع عن القيادة أو استعمال الآليات عند استعمال هذا الدواء لأنه قد يجعلك تشعر بالدوخة، التعب أو الارتباك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي أونكاسبار على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ممول من الصوديوم في كل جرعة، أي أنه أساساً &rsquo;خالٍ من الصوديوم&lsquo;.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قبل أن تُعطى أونكاسبار، قد تتلقى مجموعة من الأدوية للمساعدة في تقليل فرص إصابتك بالحساسية. سيقرر طبيبك ما إذا كان هذا العلاج التحضيري ضروريًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد وصف لك العلاج بواسطة أونكاسبار من قبل طبيب خبير بالأدوية المستعملة لعلاج السرطان. سيقرر طبيبك ما هي جرعة الدواء المطلوبة وعدد مرات إعطائها، استناد إلى عمرك ومساحة جسمك التي تحسب من طولك ووزنك.</p><p>&nbsp;</p><p dir="RTL">هذا الدواء يعطى كمحلول عن طريق الحقن في عضلة أو في الوريد إذا كان هذا مناسبا أكثر.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أعطيتَ كمية كبيرة جدا من أونكاسبار</strong></p><p dir="RTL">نظرا لأن طبيبك هو الذي سيعطيك الدواء، فمن غير المرجح أن تتلقى أكثر من حاجتك.</p><p>&nbsp;</p><p dir="RTL">في الحالة غير المرجحة لإعطاء جرعة مفرطة عن طريق الخطأ، ستوضع تحت مراقبة دقيقة من قبل فريق طبي وتُعالج بشكل مناسب.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بخصوص استعمال هذا الدواء، فاسأل طبيبك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هي الحال مع كافة الأدوية، من الممكن أن يسبب هذا الدواء تأثيرات جانبية، رغم أنها لا تصيب كافة الأشخاص.</p><p>&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية الخطيرة </strong></p><p dir="RTL">أخبر طبيبك <strong>على الفور</strong> إذا أصبت بأي من التأثيرات الجانبية التالية:</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدا (قد تصيب أكثر من 1 من 10 أشخاص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أو اضطراب بنكرياسي آخر (التهاب البنكرياس) الذي يسبب آلاما بطنية شديدة قد تنتشر إلى ظهرك، تقيؤ، زيادة في معدلات السكر في الدم.&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية خطيرة مترافقة بأعراض كالطفح، حكة، تورّم، شرى، ضيق النفس، ضربات قلب سريعة وهبوط في ضغط الدم؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى خطيرة مع حمى شديدة الارتفاع؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خثرات دموية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمّى مع عدد منخفض من خلايا الدم البيضاء.</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب حتى 1 من 10 أشخاص) </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزف شديد أو تكدّم؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رجفان شديد (نوبات) وغياب عن الوعي؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى حادة مع حمّى مرتفعة للغاية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في كبدك (أي، تغير في لون جلدك أو بولك أو خروجك ونتائج الفحوص المخبرية تشير إلى ارتفاع معدل الانزيمات الكبدية والبيليروبين).</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة: قد تصيب حتى 1 من 1.000 شخص</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور الكبد؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (الاصفرار)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف تدفق سائل المرارة من الكبد (الركود الصفراوي)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدمير خلايا الكبد (تنخر خلايا الكبد).</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>ذات معدّل حدوث غير معروف (لا يمكن تقدير معدل الحدوث من البيانات المتوفرة)</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تفاعل جلدي شديد يدعى تقشّر الأنسجة المتموتة البشروية التسممي؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقد الوظيفة الكلوية (مثل، تغير كمية البول المطروح، تورّم القدمين والكاحلين)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكتة دماغية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل تحسسي شديد قد يسبب الغياب عن الوعي وقد يكون مهددًا للحياة (صدمة تأقية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;تلف العظام (تنخر العظم).</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>التأثيرات الجانبية الأخرى</strong></p><p dir="RTL">تحدث إلى طبيبك إذا أصبت بأي مما يلي:&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدا (قد تصيب أكثر من 1 من 10 أشخاص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في وظيفة البنكرياس؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقد الوزن؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الساق (والذي قد يكون عرضا للخُثار)، ألم في الصدر أو ضيق في النفس (والذي قد يكون عرضا لحدوث خثرة دموية في الرئتين، تدعى الصمامة الرئوية)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقد الشهية، ضعف عام، تقيّؤ إسهال، غثيان؛&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدلات السكر في الدم.</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب حتى 1 من 10 أشخاص) </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناقص في عدد خلايا الدم الحمراء؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمّع السوائل في البطن (استسقاء)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى وأعراض شبيهة بالانفلونزا؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات في الفم؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر، المفاصل أو البطن؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدّلات مرتفعة للدهون والكولسترول في الدم، معدّل منخفض للبوتاسيوم في دمك.</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة (قد تصيب حتى 1 من 1.000 شخص)</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>متلازمة اعتلال بيضاء الدماغ الخلفي العكوس (RPLS)، وهي متلازمة تتصف بالصداع، الارتباك، نوبات وفقد الرؤية التي تتراجع بعد مرور بعض الوقت.</p><p>&nbsp;</p><p dir="RTL"><strong>ذات معدّل حدوث غير معروف (لا يمكن تقدير معدل الحدوث من البيانات المتوفرة)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناقص عدد خلايا الدم البيضاء والصفيحات الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمّى؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيسات بنكرياسية، تورّم الغدد اللعابية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدلات مرتفعة للبولة في الدم؛ تشكل أجسام مضادة تجاه أونكاسبار؛ معدلات مرتفعة للأمونيا في الدم؛ تناقص معدلات السكر في الدم؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس، ارتباك، نفضان خفيف في الأصابع.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا أصبت بأي تأثير جانبي تعتقد أنه على صلة بالعلاج الكيمياوي، تحدّث إلى طبيبك. وهذا يشمل أي تأثيرات جانبية غير مدرجة في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق النظام الوطني للإبلاغ. بالإبلاغ عن التأثيرات الجانبية يمكنك أيضا المساعدة بتوفير مزيد من المعلومات عن سلامة هذا الدواء.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إحتفظ بهذا الدواء بعيدا عن مرأى الأطفال ومتناول أيديهم.</p><p>&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحية المبيّن على اللصاقة والكرتونة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المشار إليه.</p><p>&nbsp;</p><p dir="RTL">احفظه في البراد (2 - 8 درجة مئوية).</p><p dir="RTL">لا تجمده.</p><p>&nbsp;</p><p dir="RTL">بعد إعادة تركيب وإذابة الدواء، يجب استعمال المحلول على الفور. إذا كان الاستعمال الفوري غير ممكن، فيمكن حفظ المحلول المذاب في درجة حرارة 2 - 8 درجة مئوية لمدة 48 ساعة.</p><p>&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء إذا كان السائل المعاد تركيبه عكرا أو يحتوي على جسيمات مرئية بالعين المجردة.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية في مياه المجاري العامة. اسأل الصيدلاني عن طريقة التخلص من الأدوية غير المستعملة. هذه&nbsp; الإجراءات تساعد على حماية البيئة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي بيغاسبارغاس. كل قنينة تحتوي على 3,750 وحدة من بيغاسبارغاس.</p><p>&nbsp;</p><p dir="RTL">بعد إعادة التركيب، يحتوي كل 1 مل من المحلول على 750 وحدة من بيغاسبارغاس (750 وحدة / مل).</p><p>&nbsp;</p><p dir="RTL">المكونات الأخرى هي: ثنائي صوديوم الفوسفات سباعية الهيدرات، ثنائي هيدروجين الفوسفات أحادية الهيدرات، كلوريد الصوديوم، سكروز، هيدروكسيد الصوديوم (لتعديل درجة الحموضة pH)، حمض الهيدروكلوريك (لتعديل درجة الحموضة pH)&nbsp; (راجع القسم 2 &quot;يحتوي أونكاسبار على الصوديوم&quot;).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أونكاسبار هو مسحوق (بودرة) أبيض إلى أبيض مصفرّ. بعد إعادة التركيب، يكون السائل الناتج صافيا، عديم اللون وخاليا من الجزيئات الغريبة المرئية.</p><p dir="RTL">تحتوي كل عبوة على قنينة زجاجية واحدة تحتوي على 3,750 وحدة بيغاسبارغاس.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق</strong></p><p dir="RTL">مختبرات سيرفييه</p><p dir="RTL">Les Laboratoires Servier</p><p dir="RTL">50, rue Carnot</p><p dir="RTL">92284 Suresnes cedex</p><p dir="RTL">France</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجهة المصنعة</strong></p><p dir="RTL">مختبرات سيرفييه الصناعية</p><p dir="RTL">Les Laboratoires Servier Industrie</p><p dir="RTL">905 Route de Saran</p><p dir="RTL">45520 Gidy</p><p dir="RTL">France</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">بلدان الخليج</p><p dir="RTL">المكتب العلمي لمختبرات سيرفييه</p><p dir="RTL">ص.ب. ١٥٨٦، الطبقة١١٥، برج أرينكو، مدينة دبي للإعلام</p><p dir="RTL">طريق الشيخ زايد، دبي</p><p dir="RTL">الإمارات العربية المتحدة</p><p dir="RTL">الهاتف: ٩٧١٤٣٣٢٩٩٠٣+</p><p dir="RTL">البريد الالكتروني</p><p dir="RTL">magdy.abdou@servier.com:</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">المكتب العلمي لشركة سيرفير العربية السعودية</p><p dir="RTL">3533 &nbsp;الحوي، &nbsp;حي حطين مكتب 101</p><p dir="RTL">الرياض، المملكة العربية السعودية</p><p dir="RTL">هاتف: &nbsp;966112522330+</p><p dir="RTL">البريدالالكتروني</p><p dir="RTL">regulatory.sa1@servier.com&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تمت آخر مراجعة لهذه النشرة في 
	07/2022
	
هـ. للإبلاغ عن التأثير(ات) الجانبية:

•	المملكة العربية السعودية

- المركز الوطني للتيقظ الدوائي (NPC)
- للاتصال بالرقم الوحد للهيئة العامة للغذاء والدواء  19999
- الهاتف المجاني: ٨٠٠٢٤٩٠٠٠٠
- البريد الالكتروني: npc.drug@sfda.gov.sa
- الموقع الالكتروني: www.sfda.gov.sa/npc

•	دول الخليج العربي الأخرى:
- الرجاء الاتصال بالسلطات المختصة ذات الصلة.

و. مجلس وزراء الصحة العرب:

إن هذا لدواء
-	الدواء مستحضر يؤثر على صحّتك، واستهلاكه خلافاً للتعليمات يعرّضك للخطر.
-	تقيّد بوصفة الطبيب، وبطريقة الاستعمال المدوّنة، وبتعليمات الصيدلاني الذي صرف لك الدواء.
-	فالطبيب والصيدلاني هما الخبيران بالدواء ونفعه وضرره.
-	لا تقطع مدة العلاج الموصوفة لك من تلقاء نفسك.
-	لا تكرر استعمال نفس الدواء دون مراجعة الطبيب.
-	لا تدع الأدوية بمتناول أيدي الأطفال.
                                                      مجلس وزراء الصحّة العرب
                                               وإتّحاد الصيادلة العرب

هـ. هذه النشرة لمعلومات المريض حائزة على موافقة الهيئة العامة للغذاء والدواء في المملكة العربية السعودية
  
	-----------------------------------------------------------------------------------------------------------------

	المعلومات التالية موجهة فقط للمهنيين ممارسي المهن الطبية:
	
	يوصى بشدة بتسجيل اسم ورقم دفعة المنتج في كل مرّة يُعطى فيها أونكاسبار لأحد المرضى، وذلك بغرض الربط بين المريض ودفعة المنتج.
	
	في ضوء عدم القدرة على توقع التفاعلات العكسية، يجب أن يعطى أونكاسبار من قبل أحد العاملين في مجال الرعاية الصحية فقط على أن يكون خبيرا في استعمال المستحضرات الدوائية الخاصة بالعلاج الكيمياوي.
	
	من الممكن أن تحدث تفاعلات فرط الحساسية تجاه أونكاسبار أثناء العلاج، كالتأق، وخاصة لدى المرضى الذين تعرف معاناتهم من فرط الحساسية تجاه الأشكال أخرى من إل- أسباراجيناز. الاحتياطات الروتينية هي مراقبة المرضى لمدة ساعة بتوفّر وجهوزية معدات الإنعاش وغيرها من المواد اللازمة لعلاج التأق (إيبينيفرين، أكسجين، الستيرويدات المعدّة  للحقن الوريدي ، إلخ).
	
	يجب إبلاغ المرضى عن إمكانية حدوث تفاعلات فرط الحساسية تجاه أونكاسبار، بما في ذلك التأق الفوري. المرضى الذين يتلقون أونكاسبار هم أكثر عرضة لإمكانية الإصابة بالنزف واضطرابات التخثر. يجب أن يشرح للمرضى أنه يجب عدم استعمال أونكاسبار في نفس وقت استعمال الأدوية الأخرى المترافقة بزيادة إمكانية النزف (راجع القسم 2 "الأدوية الأخرى و أونكاسبار").
	
	قد يسبب هذا المنتج الطبي تخرشّا عند ملامسته. لذلك يجب التعامل مع المسحوق وإعطاؤه بعناية خاصة. يجب تجنب استنشاق بخار الدواء وملامسته للجلد والأغشية المخاطية، وخاصة في العين؛ إذا لامس المنتج العينين أو الجلد أو الأغشية المخاطية، فيجب شطفه فورا بكمية كبيرة من الماء لمدة 15 دقيقة على الأقل.
	
	يجب التخلّص من أي منتج طبي غير مستعمل أو مواد متبقية بالتماشي مع المتطلبات المحليّة. 
	
	تعليمات تحضير، حفظ والتخلّص من أونكاسبار
	تعليمات الاستعمال
1.	يجب أن يكون فريق العمل مدرّبا على التعامل مع المنتج الطبي ونقله (يجب استثناء الحوامل من أفراد الفريق من العمل بهذا المنتج الطبي).
2.	يجب اعتماد التقنيات العقيمة.
3.	يجب مراعاة إجراءات التعامل المناسب مع العوامل المضادة للأورام.
4.	يوصى باستعمال القفازات النبوذة والملابس الواقية عند التعامل مع أونكاسبار.
5.	يجب أن توضع كافة الأدوات المخصصة للإعطاء أو التنظيف، بما فيها القفازات، في أكياس مخصصة للنفايات عالية الخطورة للتخلص منها عن طريق حرقها بدرجة حرارة عالية.

إعادة التركيب
1.	يحقن 5,2 مل من الماء المعدّ للحقن في القنينة باستخدام محقنة مزوّدة بإبرة قياس 21.
2.	يجب تحريك القنينة حركة دائرية بلطف إلى أن تتم إعادة تركيب المسحوق.
3.	بعد إعادة التركيب، يجب أن يكون السائل الناتج صافيا، عديم اللون وخاليا من الجزيئات الغريبة المرئية. لا تستعمله إذا كان السائل عكرا أو إذا تشكلت فيه رواسب. لا تهز القنّينة.
4.	يجب أن يستعمل المحلول في غضون 24 ساعة بعد إعادة التركيب، عندما يحفظ في درجة حرارة أقل من 25 درجة مئوية.

الإعطاء
1.	يجب فحص المستحضرات الدوائية التي تعطى عن طريق الحقن للتأكد من عدم وجود جسيمات فيها قبل إعطائها، ويمكن فقط استعمال المحلول عديم اللون، الصافي والخالي من أي جسيمات غريبة مرئية بالعين المجردة.
2.	يجب إعطاء المستحضر الدوائي عن طريق الحقن في الوريد أو في العضل. يجب إعطاء المحلول ببطء.
من أجل الإعطاء في العضل، يجب ألا يتجاوز الحجم 2 مل عند الأطفال والمراهقين و3 مل عند البالغين.
من أجل الإعطاء في الوريد، يجب تخفيف المحلول المعاد تركيبه في 100 مل من محلول كلوريد الصوديوم 9 ملغ / مل (0.9%) المعدّ للحقن أو في محلول الغلوكوز 5%. 
يمكن إعطاء المحلول المخفّف على مدى 1 - 2 ساعة مع سائل تسريب جارٍ بالفعل إما من محلول كلوريد الصوديوم 9 ملغ / مل (0.9%) أو من محلول الغلوكوز 5%. لا تسرّب منتجات دوائية أخرى في نفس الخطّ الوريدي اثناء إعطاء أونكاسبار.
يجب أن يستعمل المحلول مباشرة بعد تخفيفه. إذا لم يكن الاستعمال الفوري ممكنا، فيمكن حفظ المحلول المخفّف ضمن درجة حرارة 2 - 8 درجة مئوية لمدة تصل إلى 48 ساعة.

التخلّص
	أونكاسبار معدّ للاستعمال مرة واحدة فقط. يجب التخلّص من أي منتج طبي غير مستعمل أو مواد متبقية بالتماشي مع المتطلبات المحليّة. 
	يمكن الحصول على المزيد من المعلومات التفصيلية في موجز خصائص المستحضر.
	


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oncaspar 750 U/ml powder for solution for injection/infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 3,750 Units (U)** of pegaspargase*.
After reconstitution, 1 ml of solution contains 750 U pegaspargase (750 U/ml).

*  The  active  substance  is  a  covalent  conjugate  of  Escherichia coli-derived  L-asparaginase  with monomethoxypolyethylene glycol
**One unit is defined as the quantity of enzyme required to liberate 1 µmol ammonia per minute at pH 7.3 and 37°C

The potency of this medicinal product should not be compared to the one of another pegylated or non-pegylated protein of the same therapeutic class. For more information, see section 5.1.

For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection/infusion. White to off-white powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oncaspar should be prescribed and administered by physicians and/or health care personnel experienced in the use of antineoplastic products. It should only be given in a hospital setting where appropriate resuscitation equipment is available. Patients should be closely monitored for any adverse reactions throughout the administration period (see section 4.4).</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Oncaspar &nbsp;is &nbsp;usually &nbsp;administered &nbsp;as &nbsp;part &nbsp;of &nbsp;combination &nbsp;chemotherapy &nbsp;protocols &nbsp;with &nbsp;other antineoplastic agents (see also section 4.5).</p><p>&nbsp;</p><p><em>Recommended premedication </em></p><p><em>Premedicate patients with paracetamol, an H-1 receptor blocker (e.g. diphenhydramine), and an H-2 receptor blocker (e.g. famotidine) 30-60 minutes prior to administration of Oncaspar to decrease the risk and severity of both infusion and hypersensitivity reactions (see section 4.4).</em></p><p>&nbsp;</p><p><em><u>Paediatric</u></em><em><u> patients and adults &le;21 years</u></em></p><p>The recommended dose in patients with a body surface area (BSA) &ge;0.6 m2&nbsp;and who are &le;21 years of age is 2,500 U of pegaspargase (equivalent to 3.3 ml Oncaspar)/m2&nbsp;body surface area every 14 days.</p><p>&nbsp;</p><p>Children with a body surface area &lt;0.6 m2&nbsp;should receive 82.5 U of pegaspargase (equivalent to 0.1 ml Oncaspar)/kg body weight every 14 days.</p><p>&nbsp;</p><p><em><u>Adults</u></em><em><u> &gt;21 years</u></em></p><p>Unless otherwise prescribed, the recommended&nbsp; posology in&nbsp; adults aged&nbsp; &gt;21 years is 2,000 U of pegaspargase (equivalent to 2.67 ml Oncaspar)/m2&nbsp;body surface area every 14 days.</p><p>&nbsp;</p><p>Treatment may be monitored based on the trough serum asparaginase activity measured before the next administration of pegaspargase. If asparaginase activity values fail to reach target levels, a switch to a different asparaginase preparation could be considered (see section 4.4).</p><p>&nbsp;</p><p><em><u>Special</u></em><em><u> populations</u></em><em> </em><em>Renal</em><em> </em><em>impairment</em></p><p>As pegaspargase is a protein with a high molecular weight, it is not excreted renally, and no dose adjustment is necessary in patients with renal impairment.</p><p>&nbsp;</p><p><em>Hepatic</em><em> impairment</em></p><p>No dose adjustment is necessary in patients with hepatic impairment.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>There are limited data available for patients older than 65 years. <u>Method of administration</u></p><p>Oncaspar can be given by intramuscular (IM) injection or intravenous (IV) infusion.</p><p>&nbsp;</p><p>For smaller volumes, the preferred route of administration is intramuscular. When Oncaspar is given by intramuscular injection the volume injected at one site should not exceed 2 ml in children and adolescents and 3 ml in adults. If a higher volume is given, the dose should be divided and given at several injection sites.</p><p>&nbsp;</p><p>Intravenous infusion of Oncaspar is usually given over a period of 1 to 2 hours in 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution.</p><p>&nbsp;</p><p>The diluted solution can be given together with an already-running infusion of either sodium chloride 9 mg/ml or 5% glucose. Do not infuse other medicinal products through the same intravenous line during administration of Oncaspar.</p><p>&nbsp;</p><p>For instructions on reconstitution and dilution of this medicinal product before administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Severe hepatic impairment (bilirubin >3 times upper limit of normal [ULN]; transaminases >10 times ULN).
History of serious thrombosis with prior L-asparaginase therapy.
History  of  pancreatitis,  including  pancreatitis  related  to  previous  L-asparaginase  therapy  (see section 4.4).
History of serious haemorrhagic events with prior L-asparaginase therapy (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Asparaginase antibodies</u></p><p>The presence of anti-asparaginase antibodies may be associated with low asparaginase activity levels due to potential neutralising activity of these antibodies. In such cases, a switch to a different asparaginase preparation should be considered.</p><p>&nbsp;</p><p>Measurement of the asparaginase activity level in serum or plasma may be undertaken in order to rule out an accelerated reduction of asparaginase activity.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Hypersensitivity reactions to pegaspargase, including life-threatening anaphylaxis, can occur during therapy, including in patients with known hypersensitivity to <em>E. coli </em>derived &nbsp;asparaginase formulations. Other hypersensitivity reactions can include angioedema, lip swelling, eye swelling, erythema, decreased blood pressure, bronchospasm, dyspnoea, pruritus and rash (see sections 4.3 and 4.8).</p><p>&nbsp;</p><p>Premedicate patients 30-60 minutes prior to administration of Oncaspar (see section 4.2).</p><p>&nbsp;</p><p>As a routine precautionary measure, the patient should be monitored for an hour after administration; resuscitation equipment and other appropriate means for the treatment of anaphylaxis should be available (epinephrine, oxygen, intravenous steroids, etc.). Oncaspar should be discontinued in patients with serious hypersensitivity reactions (see sections 4.3 and 4.8). Depending on the severity of the symptoms, administration of antihistamines, corticosteroids and vasopressors may be indicated as a counter-measure.</p><p>&nbsp;</p><p><u>Pancreatic effects</u></p><p>Pancreatitis, including haemorrhagic or necrotising pancreatitis with fatal outcomes, has been reported in patients receiving Oncaspar (see section 4.8).</p><p>&nbsp;</p><p>Patients should be informed of the signs and symptoms of pancreatitis which, if left untreated, could become fatal.</p><p>&nbsp;</p><p>If pancreatitis is suspected, Oncaspar should be discontinued; if pancreatitis is confirmed, Oncaspar should not be restarted.</p><p>&nbsp;</p><p>Serum amylase and/or lipase levels should be monitored frequently to identify early signs of pancreatic inflammation. Blood glucose levels should be monitored, as impaired glucose tolerance may occur with concomitant use of Oncaspar with prednisone.</p><p>&nbsp;</p><p><u>Coagulopathy</u></p><p>Serious thrombotic events, including sagittal sinus thrombosis can occur in patients receiving pegaspargase (see section 4.8). Oncaspar should be discontinued in patients with serious thrombotic events.</p><p>&nbsp;</p><p>Increased prothrombin time (PT), increased partial thromboplastin time (PTT), and hypofibrinogenaemia can occur in patients receiving pegaspargase. Coagulation parameters should be monitored at baseline and periodically during and after treatment, particularly when other medicinal products with anticoagulant effects (such as acetylsalicylic acid and non-steroidal anti-inflammatory medicinal products) are used simultaneously (see section 4.5), or when concomitant chemotherapy regimen including methotrexate, daunorubicin, corticosteroids is administered. When there is a marked decrease in fibrinogen or antithrombin III (ATIII) deficiency, consider &nbsp;appropriate replacement therapy.</p><p>&nbsp;</p><p><u>Osteonecrosis</u></p><p>In the presence of glucocorticoids, osteonecrosis (avascular necrosis) is a possible complication of hypercoagulability observed in children and adolescents with a higher incidence seen in girls (see section 4.5 and 4.8). Therefore, a close monitoring in children and adolescents&rsquo; patients is recommended in order to detect any clinical signs/symptoms of osteonecrosis. Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment as per standard guidelines of treatment of ALL and supportive care principles.</p><p>&nbsp;</p><p><u>Hepatic effects</u></p><p>Combination therapy with Oncaspar and other hepatotoxic products can result in severe hepatic toxicity.</p><p>&nbsp;</p><p>Caution is required when Oncaspar is given in combination with hepatotoxic products, especially if there is pre-existing hepatic impairment. Patients should be monitored for changes in liver function parameters.</p><p>&nbsp;</p><p>There may be an increased risk of hepatotoxicity in Philadelphia chromosome positive patients, for whom treatment with tyrosine kinase inhibitors (e.g., imatinib) is combined with L-asparaginase therapy. This should be taken into account when considering the use of Oncaspar in these patient populations.</p><p>&nbsp;</p><p>Due to the risk of hyperbilirubinaemia, it is recommended to monitor bilirubin levels at baseline and prior to each dose.</p><p>&nbsp;</p><p><u>Central nervous system effects</u></p><p>Combination therapy with Oncaspar can result in central nervous system toxicity. Cases of encephalopathy (including reversible posterior leukoencephalopathy syndrome) have been reported (see section 4.8).</p><p>&nbsp;</p><p>Oncaspar may cause central nervous system signs and symptoms manifesting as somnolence, confusion, convulsions. Patients should be closely monitored for such symptoms, especially if Oncaspar is used in association with neurotoxic products (such as vincristine and methotrexate; see section 4.5),</p><p>&nbsp;</p><p><u>Myelosuppression</u></p><p>Pegaspargase may cause myelosuppression, either directly or indirectly (by altering myelosuppressive effects of other agents such as methotrexate or 6-mercaptopurine). Therefore, use of Oncaspar could increase the risk of infections.</p><p>&nbsp;</p><p>The decrease in the number of circulating lymphoblasts is often quite marked, and normal or too low leukocyte counts are often seen in the first days after the start of therapy. This can be associated with a marked rise in the serum uric acid level. Uric acid nephropathy may develop. To monitor the therapeutic effect, the peripheral blood count and the patient&rsquo;s bone marrow should be monitored closely.</p><p>&nbsp;</p><p><u>Hyperammonaemia</u></p><p>Asparaginase facilitates the rapid conversion of asparagine and glutamine to aspartic acid and glutamic acid, with ammonia as the shared by-product of both reactions (see section 5.1). Intravenous administration of asparaginase may therefore cause serum levels of ammonia to rise sharply following administration.</p><p>&nbsp;</p><p>The symptoms of hyperammonaemia are often transient in nature and can include: nausea, vomiting, headache, dizziness and rash. In severe cases, encephalopathy can develop with or without hepatic impairment, especially in older adults, which can be life-threatening or fatal. If symptoms of hyperammonaemia exist, ammonia levels should be monitored closely.</p><p>&nbsp;</p><p><u>Contraception</u></p><p>Effective non-oral method of contraception must &nbsp;be &nbsp;used &nbsp;during &nbsp;Oncaspar &nbsp;treatment &nbsp;and &nbsp;for &nbsp;at least 6 months after Oncaspar discontinuation. Since an indirect interaction between the oral contraceptives and pegaspargase cannot be ruled out, the use of oral contraception is not considered an acceptable method of contraception (see sections 4.5 and 4.6).</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say, essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The decrease in serum proteins caused by pegaspargase can increase the toxicity of other medicinal products that are protein bound.</p><p>&nbsp;</p><p>In addition, by inhibiting protein synthesis and cell division, pegaspargase can disturb the mechanism of action of other substances which require cell division for their effect, e.g., methotrexate.</p><p>Methotrexate and cytarabine can interact differently with Oncaspar: their prior administration can increase the action of pegaspargase synergistically. If these substances are given subsequently, the effect of pegaspargase can be weakened antagonistically.</p><p>&nbsp;</p><p>Pegaspargase can interfere with metabolism and clearance of other medicinal products, based on its effects on protein synthesis and hepatic function, as well as from its combined use with other chemotherapy products known to interact with CYP enzymes.</p><p>&nbsp;</p><p>The use of Oncaspar can lead to fluctuation in coagulation factors. This can promote the tendency to bleeding and/or thrombosis. Caution is therefore needed when anticoagulants such as coumarin, heparin, dipyridamole, acetylsalicylic acid or non-steroidal anti-inflammatory medicinal products are given concomitantly, or when concomitant chemotherapy regimen including methotrexate, daunorubicin, corticosteroids is administered.</p><p>&nbsp;</p><p>When glucocorticoids (e.g., prednisone) and pegaspargase are given at the same time, alterations in coagulation parameters (e.g., fall in fibrinogen and antithrombin III deficiency, ATIII) can be more pronounced.</p><p>&nbsp;</p><p>Pegaspargase may increase the risk of glucocorticoid-induced osteonecrosis in children and adolescents when both treatments are given simultaneously, with a higher incidence seen in girls, through a potential increase in exposure of dexamethasone. (see sections 4.4 and 4.8).</p><p>Immediately preceding or simultaneous treatment with vincristine can increase the toxicity of pegaspargase. Administration of Oncaspar before vincristine may increase the neurotoxicity of vincristine. Therefore, vincristine should be given at least 12 hours prior to administration of Oncaspar in order to minimise toxicity.</p><p>&nbsp;</p><p>An indirect interaction cannot be ruled out between pegaspargase and oral contraceptives due to pegaspargase hepatotoxicity that may impair the hepatic clearance of oral contraceptives. Therefore, the concomitant use of Oncaspar with oral contraceptives is not recommended. Another method than oral contraception should be used in women of childbearing potential (see sections 4.4 and 4.6).</p><p>&nbsp;</p><p>Simultaneous vaccination with live vaccines may increase the risk of severe infections attributable to the immunosuppressive activity of pegaspargase, the presence of the underlying disease and combination chemotherapy (see section 4.4). Vaccination with live vaccines should therefore be given no earlier than 3 months after termination of the entire antileukaemic treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p>Men and women should use effective contraception during treatment and for at least 6 months after Oncaspar discontinuation. Since an indirect interaction between oral contraceptives and pegaspargase cannot be ruled out , oral contraceptives are not considered sufficiently safe in such clinical situation. A method other than oral contraception should be used in women of childbearing potential (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are limited data on the use of L-asparaginase and no data on the use of Oncaspar in pregnant women. No reproduction studies in animals with pegaspargase were performed but studies in animals with L-asparaginase have shown teratogenicity (see section 5.3). Therefore and due to its pharmacological properties, Oncaspar should not be used during pregnancy unless the clinical conditions of the woman require treatment with pegaspargase.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is not known whether pegaspargase is excreted in breast milk. Based on its pharmacological properties, any risk to the breast-fed newborns/infants cannot be excluded. As a precautionary measure, breast-feeding should be discontinued during treatment with Oncaspar and should not be restarted until after discontinuation of Oncaspar.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No studies investigating the effect of pegaspargase on fertility have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Oncaspar has a major influence on the ability to drive and use machines. The following adverse reactions have been reported in patients treated with Oncaspar along with other chemotherapy medicinal products: somnolence, confusion, dizziness, syncope, seizure.</p><p>Patients should be advised not to drive or operate machines while receiving Oncaspar if they experience these or other adverse reactions which can impair their ability to drive or operate machines (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The adverse reactions described in this section are derived from studies data and post-marketing experience of Oncaspar in ALL patients. The safety profile is based on randomised, controlled, prospective, open label multicentre studies using Oncaspar at a dose of 2500 U/m2&nbsp;administered intravenously as a comparative treatment (studies DFCI 11-001 and AALL07P4). In addition, Oncaspar studies using the intramuscular route of administration (studies CCG-1962 and CCG-1991) were also considered to determine the safety profile (see section 5.1).</p><p>&nbsp;</p><p>The most common adverse reactions with Oncaspar (observed in at least 2 studies with a frequency of</p><p>&gt;10%) included: alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, activated partial thromboplastin time prolonged, hypertriglyceridaemia, hyperglycaemia, and febrile neutropenia.</p><p>&nbsp;</p><p>The most common, severe adverse reactions with Oncaspar &nbsp;(graded 3 &nbsp;or 4) &nbsp;observed &nbsp;in &nbsp;studies DFCI 11-001 and AALL07P4 with a frequency of &gt;5% included: alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, febrile neutropenia, hyperglycaemia, lipase increased, and pancreatitis.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions and their frequencies are reported in Table 1. Frequencies are defined by the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to</p><p>&lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table 1: Adverse reactions reported with Oncaspar therapy</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>standard system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse</strong><strong> </strong><strong>reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common: Infections, sepsis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common: Febrile neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Common: Anaemia, coagulopathy</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Bone marrow failure</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Very common: Hypersensitivity, urticaria, anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Anaphylactic shock.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Metabolism &nbsp;and &nbsp;nutrition disorders</p></td><td style="vertical-align:top"><p>Very common: Decreased appetite, hyperglycaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common: Hyperlipidaemia, hypercholesterolaemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Diabetic ketoacidosis, hypoglycaemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Not known: Confusional state</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common: Seizure, peripheral motor neuropathy, syncope</p></td></tr><tr><td style="vertical-align:top"><p>Rare: Posterior reversible leukoencephalopathy syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Somnolence, tremor*</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very common: Embolism**</p></td></tr><tr><td style="vertical-align:top"><p>Common: Thrombosis***</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Cerebrovascular accident, haemorrhage, superior sagittal sinus thrombosis</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, &nbsp;thoracic &nbsp;and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common: Hypoxia</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common: Pancreatitis, diarrhoea, abdominal pain, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common: Vomiting, stomatitis, ascites</p></td></tr><tr><td style="vertical-align:top"><p>Rare: Pancreatitis necrotising, pancreatitis haemorrhagic</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Pancreatic pseudocyst, parotitis*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common: Hepatotoxicity, fatty liver</p></td></tr><tr><td style="vertical-align:top"><p>Rare: Hepatic necrosis, jaundice, cholestasis, hepatic failure</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common: Rash</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Toxic epidermal necrolysis*</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common: Pain in extremities</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp; &nbsp; Not known: Osteonecrosis (see sections 4.4 and 4.5)</td></tr><tr><td style="vertical-align:top"><p>Renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary disorders</p></td><td style="vertical-align:top"><p>Not known: Renal failure acute*</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; site conditions</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Not known: Pyrexia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Investigations</p></td><td style="vertical-align:top"><p>Very common: Weight decreased, hypoalbuminaemia, alanine aminotransferase increased, aspartate aminotransferase increased, hypertriglyceridaemia, blood fibrinogen decreased, lipase increased, amylase increased, activated partial thromboplastin time prolonged, blood bilirubin increased</p></td></tr><tr><td style="vertical-align:top"><p>Common: Prothrombin time prolonged. international normalised ratio increased, hypokalaemia, blood cholesterol increased, hypofibrinogenaemia, gamma-glutamyl transferase increased</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Blood urea increased, anti-pegaspargase antibodies, neutrophil count decreased, platelet count decreased, hyperammonaemia</p></td></tr></tbody></table><p>*Adverse reactions observed with other asparaginases in the class</p><p>**Cases of pulmonary embolism, venous thrombosis, venous thrombosis limb, and thrombophlebitis superficial were observed in DFCI 11-001</p><p>***Legend: CNS thrombosis</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>The following adverse reactions have been observed in association with asparaginase therapy. Although they have not been specifically associated with the use or pegaspargase, they may occur with the use of Oncaspar:</p><p>&nbsp;</p><p><em>Blood and lymphatic system disorders</em></p><p>Oncaspar can cause mild to moderate myelosuppression, and all three blood cell lines can be affected. About half of all serious haemorrhages and thromboses affect cerebral vessels and can lead to e.g., stroke, seizure, headache or loss of consciousness.</p><p>&nbsp;</p><p><em>Nervous</em><em> </em><em>system</em><em> disorders</em></p><p>Oncaspar &nbsp;may &nbsp;cause &nbsp;central &nbsp;nervous &nbsp;system &nbsp;dysfunctions &nbsp;manifesting &nbsp;as &nbsp;convulsions, &nbsp;and &nbsp;less frequently confusional state and somnolence (mildly impaired consciousness).</p><p>In rare cases, a reversible posterior leukoencephalopathy syndrome (RPLS) may occur. In very rare cases, mild tremor in the fingers has been described.</p><p>&nbsp;</p><p><em>Gastrointestinal</em><em> </em><em>disorders</em></p><p>About half of patients develop mild to moderate gastrointestinal reactions such as loss of appetite, nausea, vomiting, abdominal cramps, diarrhoea and weight loss.</p><p>Acute pancreatitis can occur commonly. There have been isolated reports of formation of pseudocysts (up to four months after the last treatment).</p><p>&nbsp;</p><p>Haemorrhagic or necrotising pancreatitis occurs rarely. One case of pancreatitis with simultaneous acute parotitis has been described with L-asparaginase treatment. In single cases, haemorrhagic or necrotising pancreatitis with fatal outcome has been reported.</p><p>Serum amylase can rise during and also after the conclusion of Oncaspar therapy.</p><p>&nbsp;</p><p><em>Renal and urinary disorders</em></p><p>Acute &nbsp;renal &nbsp;failure &nbsp;may &nbsp;develop &nbsp;in &nbsp;rare &nbsp;cases &nbsp;during &nbsp;treatment &nbsp;with &nbsp;L-asparaginase-containing regimens.</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>Allergic reactions can manifest on the skin. One case of toxic epidermal necrolysis (Lyell&lsquo;s syndrome) has been described in association with L-asparaginase.</p><p>&nbsp;</p><p><em>Endocrine</em><em> disorders</em></p><p>Alterations in endocrine pancreatic function are observed commonly and are expressed mainly in the form of abnormal glucose metabolism. Both diabetic ketoacidosis and hyperosmolar hyperglycaemia have been described, which generally respond to administration of insulin.</p><p>&nbsp;</p><p><em>Metabolism</em><em> and nutrition disorders</em></p><p>An alteration in serum lipid levels was observed and changes in serum lipid values, in most cases without clinical symptoms, are very common.</p><p>A rise in serum urea occurs regularly, is dose-independent and nearly always a sign of pre-renal metabolic imbalance.</p><p>&nbsp;</p><p><em>General</em><em> </em><em>disorders</em><em> </em><em>and administration site conditions</em></p><p>Pyrexia can occur after the injection, which usually subsides spontaneously.</p><p>&nbsp;</p><p><em>Immune</em><em> system disorders</em></p><p>Specific&nbsp; antibodies&nbsp; to pegaspargase&nbsp; have&nbsp; been &nbsp;detected; &nbsp;uncommonly they&nbsp; were&nbsp; associated &nbsp;with hypersensitivity reactions. Neutralising antibodies reducing clinical efficacy were also recorded.</p><p>&nbsp;</p><p>Hypersensitivity reactions to Oncaspar, including life-threatening anaphylaxis, angioedema, lip swelling, eye swelling, erythema, blood pressure decreased, bronchospasm, dyspnoea, pruritus and rash, can occur during therapy (see sections 4.3 and 4.4).</p><p><em>Hepatobiliary</em><em> disorders</em></p><p>Alteration of liver parameters is common. A dose-independent rise in serum transaminases, and serum bilirubin is commonly observed.</p><p>Fatty liver can be observed very frequently. There have been rare reports of cholestasis, icterus, hepatic cell necrosis and hepatic failure with fatal outcome.</p><p>Impaired protein synthesis can lead to a decline in the serum proteins. There is a dose-independent decrease in serum albumin in the majority of patients during the treatment.</p><p>The types of adverse reactions with Oncaspar are similar to those observed with native non-pegylated L-asparaginase (e.g., native <em>E. coli </em>asparaginase).</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the beneﬁt/risk balance of the medicinal product. Healthcare</p><p>.professionals are asked to report any suspected adverse reactions via the national reporting syﬆem</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><p>&nbsp;</p><p>-&nbsp; National Pharmacovigilance Center (NPC)</p><p><!--[if gte vml 1]><v:group
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:375.3pt;margin-top:8.65pt;width:127.85pt;height:12.6pt;z-index:251644928;
 mso-position-horizontal-relative:page' coordorigin="7506,173" coordsize="2557,252">
 <v:shape id="_x0000_s1027" style='position:absolute;left:7506;top:173;width:2557;
  height:252' coordorigin="7506,173" coordsize="2557,252" path="m7506,425r2557,l10063,173r-2557,l7506,425xe"
  fillcolor="silver" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="170" height="17" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/16/clip_image001.gif" />- Fax: +966-11-205-7662</p><p>-&nbsp; SFDA call Center 19999</p><p>-&nbsp; Toll free phone: 8002490000</p><p>-&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp; Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC states:</p><p>&nbsp;</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cases of accidental overdose have been reported with Oncaspar. Following overdose, increased liver enzymes, rash and hyperbilirubinaemia have been observed. There is no specific pharmacological treatment for the overdose. In case of overdose, patients must be carefully monitored for signs and symptoms of adverse reactions, and appropriately managed with symptomatic and supportive treatment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic and immunomodulating agents, other antineoplastic agents, ATC code: L01XX24</p><p><u>Mechanism of action</u></p><p>The mechanism of action of L-asparaginase is the enzymatic cleavage of the amino acid L-asparagine into aspartic acid and ammonia. Depletion of L-asparagine in blood results in inhibition of protein-synthesis, DNA-synthesis and RNA-synthesis, especially in leukaemic blasts which are not able to synthesise L-asparagine, thus undergoing apoptosis.</p><p>Normal cells, in contrast, are capable of synthesising L-asparagine and are less affected by its rapid depletion during treatment with the enzyme L-asparaginase. The PEGylation does not change the enzymatic properties of L-asparaginase, but it influences the pharmacokinetics and immunogenicity of the enzyme.</p><p><u>Pharmacodynamic effects</u></p><p>Anti-leukaemic effect of L-asparaginase is related to a sustained L-asparagine depletion in blood and cerebrospinal fluid (CSF). The pharmacodynamic (PD) effect of Oncaspar was assessed after intramuscular (Study CCG-1962) and intravenous administration (AALL07P4).</p><p>In Study CCG-1962, PD effect of Oncaspar was assessed through serial measurements of asparagine in serum (n=57) and CSF (n=50) of newly diagnosed paediatric patients with standard-risk ALL who received three intramuscular doses of Oncaspar (2,500 Units/m2&nbsp;BSA), one each during induction and two during delayed intensification treatment phases. A reduction in serum asparagine concentration was evident by the 4th day after the first Induction dose and reached an apparent nadir by the 10th day after the dose. Serum asparagine concentrations of approximately 1 &micro;M persisted for approximately 3 weeks. Asparagine concentration fell to &lt;3 &micro;M when asparaginase activity was &gt;0.1 U/mL. CSF asparagine of 2.3 &micro;M pre-treatment fell to 1.1 &micro;M on Day 7 and 0.6 &micro;M on Day 28 of Induction (see Clinical efficacy and safety).</p><p>In Study AALL07P4, the PD effect of Oncaspar was assessed in 47 evaluable subjects with high risk B-precursor ALL who received intravenous doses of Oncaspar 2,500 U/m2&nbsp;BSA during the Induction and Consolidation phases. Plasma L-asparagine concentrations were depleted to below the assay limit of quantification within 24 hours following the Induction and first Consolidation dose of Oncaspar and depletion was sustained for approximately two weeks. CSF asparagine concentrations were reduced by the 4th day following the Induction dose, and remained largely undetectable by the 18th day after dosing.</p><p>&nbsp;</p><p>Based on results from these two studies, a 2,500 U/m2&nbsp;BSA dose of Oncaspar administered intramuscular (CCG-1962) and intravenous (AALL07P4) provides maintenance of L-asparagine depletion for approximately two weeks following dosing.</p><p><u>Clinical efficacy and safety</u></p><p>Oncaspar efficacy and safety were evaluated on the basis of three clinical studies using Oncaspar solution for injection/infusion in the first line treatment of ALL: Study CCG-1962 in standard risk ALL patients; Study AALL07P4 in high risk ALL patients; Study DFCI 11-001 enrolled both standard and high-risk ALL patients.</p><p>Oncaspar efficacy in ALL in patients with relapse/refractory disease and a history of prior clinical allergic reaction to native <em>E. coli </em>L-asparaginase was based on a pool of 94 patients from six open-label studies [ASP-001, ASP-201A, ASP-302, ASP-304, ASP-400 and ASP-001C/003C].</p><p><em><u>First-Line</u></em><em><u> (ALL patients non-hypersensitive to native E. coli L-asparaginase)</u></em></p><p>The safety and efficacy of Oncaspar was evaluated in an open-label, multicentre, randomised, active-controlled study (Study CCG-1962). In this study, 118 paediatric patients aged 1 to 9 years with previously untreated standard-risk ALL were randomised 1:1 to Oncaspar or native <em>E. coli </em>L-asparaginase as part of combination therapy. Oncaspar was administered intramuscularly at a dose of 2,500 Units/m2&nbsp;BSA on Day 3 of the 4-week Induction phase and on Day 3 of each of two 8-week Delayed Intensification (DI) phases. Native <em>E. coli </em>L-asparaginase was administered intramuscularly at a dose of 6,000 Units/m2&nbsp;BSA three times weekly for a total of 9 doses during induction and for a total of 6 doses during each delayed intensification phase.</p><p>&nbsp;</p><p>The primary determination of efficacy was based on demonstration of similar asparagine depletion (magnitude and duration) in the Oncaspar and native <em>E.</em><em> coli </em>L-asparaginase arms. The protocol-specified goal was achievement of asparagine depletion to a serum concentration of &pound;1 mM. The proportion of patients with this level of depletion was similar between the 2 study arms during all 3 phases of treatment at the protocol-specified time points.</p><p>&nbsp;</p><p>In all phases of treatment, serum asparagine concentrations decreased within 4 days of the first dose of asparaginase in the treatment phase and remained low for approximately 3 weeks for both Oncaspar and native <em>E. coli </em>L-asparaginase arms. Serum asparagine concentrations during the induction phase are shown in Figure 1. The patterns of serum asparagine depletion in the 2 delayed intensification phases are similar to the pattern of serum asparagine depletion in the induction phase.</p><p>&nbsp;</p><p>Figure 1: Mean (&plusmn; standard error) serum asparagine during Study CCG-1962 induction phase</p><p><img src="data:image/png;base64,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" alt="" width="942" height="421" vspace="0" hspace="0" border="0" style="width:942px;height:421px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><strong>&nbsp;</strong></p><p><span style="text-align:unset">Note: Oncaspar (2,500 Units/m2&nbsp;BSA intramuscular) was administered on Day 3 of the 4-week induction phase. Native </span><em style="text-align:unset">E. coli </em><span style="text-align:unset">L-asparaginase (6,000 Units/m2&nbsp;BSA intramuscular) was administered 3 times weekly for 9 doses during induction.</span></p><p>&nbsp;</p><p>CSF &nbsp;asparagine &nbsp;concentrations &nbsp;were &nbsp;determined &nbsp;in &nbsp;50 patients &nbsp;during &nbsp;the &nbsp;induction &nbsp;phase. &nbsp;CSF asparagine decreased from a mean pre-treatment concentration of 3.1 &micro;M to 1.7 &micro;M on Day 4 &plusmn; 1 and</p><p>&nbsp;</p><p>1.5 &micro;M at 25 &plusmn; 1 days after administration of Oncaspar. These findings were similar to those observed in the native <em>E.</em><em> coli </em>L-asparaginase treatment arm.</p><p>&nbsp;</p><p>Event-free survival (EFS) for the Oncaspar and native <em>E. coli </em>L-asparaginase arms is summarised in Table 2, Study CCG-1962 was not designed to evaluate differences in EFS rates.</p><p>&nbsp;</p><p>Table 2: Event-free survival rate at 3, 5 and 7 years (Study CCG-1962)</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oncaspar</p></td><td style="vertical-align:top"><p>native <em>E. coli </em>L-asparaginase</p></td></tr><tr><td style="vertical-align:top"><p>3-Year EFS Rate, % (95% CI)</p></td><td style="vertical-align:top"><p>83</p><p>(73, 93)</p></td><td style="vertical-align:top"><p>79</p><p>(68, 90)</p></td></tr><tr><td style="vertical-align:top"><p>5-Year EFS Rate, % (95% CI)</p></td><td style="vertical-align:top"><p>78</p><p>(67, 88)</p></td><td style="vertical-align:top"><p>73</p><p>(61, 85)</p></td></tr><tr><td style="vertical-align:top"><p>7-Year EFS Rate, % (95% CI)</p></td><td style="vertical-align:top"><p>75</p><p>(63, 87)</p></td><td style="vertical-align:top"><p>66</p><p>(52, 80)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>In Study CCG-1962, the most common adverse reactions were infections, including two life-threatening infections (1 patient in each arm). In general, incidence and type of adverse reactions Grade 3 and 4 were similar between the two treatment groups. Two patients in the Oncaspar arm had allergic reactions during Delayed Intensification (DI) DI #1 (Grade 1 allergic reaction and Grade 3 hives).</p><p>&nbsp;</p><p>A pilot study was conducted for newly diagnosed patients from 1 to &lt;31 years of age with high risk B-precursor ALL (Study AALL07P4). This was an open label, controlled, randomised study comparing an investigational pegylated asparaginase product to Oncaspar as a component of multi-agent chemotherapy in the first line treatment of ALL. White blood cell (WBC) criteria were:</p><p>a) Age 1-10 years: WBC &ge;50,000/&mu;L; b) Age 10-30 years: Any WBC; c) Prior steroid therapy: Any WBC. Patients were not allowed prior cytotoxic chemotherapy with the exception of steroids and intrathecal cytarabine. A total of 166 patients were enrolled in this study; 54 patients were randomised to treatment with 2,500 U/m2&nbsp;BSA Oncaspar and 111 patients were randomised to the investigational pegylated &nbsp;asparaginase &nbsp;product. &nbsp;Oncaspar &nbsp;was &nbsp;administered &nbsp;intravenously &nbsp;at&nbsp; &nbsp;the&nbsp; &nbsp;dose&nbsp; &nbsp;of 2,500 Units/m2&nbsp;BSA during Induction, Consolidation, Delayed Intensification, and Interim Maintenance phases in patients with high-risk ALL receiving augmented Berlin-Frankfurt-M&uuml;nster therapy. The percentage of patients in the Oncaspar treatment arm with evaluable minimal residual disease (MRD) negative status (&lt;0.1% leukaemia cells in bone marrow) at Day 29 of Induction was 80% (40/50). At 4-years, the EFS and overall survival (OS) for the Oncaspar treatment arm were 81.8% [95% CI 62.9-91.7%] and 90.4% [95% CI 78.5-95.9%], respectively. Overall, in the group receiving Oncaspar, the rate of all grade hypersensitivity was 5.8%, anaphylactic reactions was 19.2%, and pancreatitis 7.7%. Grade 3 or higher febrile neutropenia was 15.4%.</p><p>&nbsp;</p><p>Study DFCI 11-001, conducted by the Dana-Farber Cancer Institute (DFCI), is an ongoing, active-controlled, randomised multicentre study of an intravenous investigational pegylated asparaginase product <em>versus </em>Oncaspar, in children and adolescents aged 1 to &lt;22 years with newly diagnosed ALL treated with a DFCI ALL consortium therapeutic backbone. A total of 239 patients were randomised, 237 of whom were treated with study drug (146 male and 91 female), of these, 119 patients (115 with a diagnosis of ALL) were treated with Oncaspar 2500 U/m2. Treatment was administered during Induction (Day 7), and then every 2 weeks for a total of 30 weeks post-Induction therapy. Randomisation of patients was stratified based on risk group (standard/high/very high risk), including both B- and T-cell ALL. The percentage of patients in the Oncaspar arm with evaluable Low End-Induction MRD (&lt;0.001 detectable disease) at Day 32 was 87.9% (80/91). The One-year EFS was 98.0 [95%CI 92.3, 99.5]; the One-year OS was 100 [95% CI 100, 100] in this study.</p><p>&nbsp;</p><p><em><u>ALL</u></em><em><u> patients hypersensitive to native E. coli L-asparaginase</u></em></p><p>Six open-label studies evaluated Oncaspar in relapse/refractory haematological diseases. In these studies a total of 94 patients with ALL diagnosis with a history of prior clinical allergic reaction to native <em>E. coli </em>L-asparaginase were exposed to Oncaspar. One patient received Oncaspar doses of 250 and &nbsp;500 Units/m2&nbsp;&nbsp; &nbsp;BSA &nbsp;intravenously. &nbsp;The &nbsp;remaining &nbsp;patients &nbsp;were &nbsp;treated &nbsp;with &nbsp;2,000 or</p><p>&nbsp;</p><p>2,500 U/m2&nbsp;BSA administered&nbsp; intramuscularly&nbsp; or intravenously. Patients&nbsp; received Oncaspar as&nbsp; a single agent or in combination with multi-agent chemotherapy. Overall, from five studies analysed based on 65 ALL patients exposed to Oncaspar using the highest therapeutic response during the entire study, complete remission was observed in 30 patients (46%), partial remission in 7 patients (11%) and haematological improvement in 1 patient (2%). In the other study, with 29 hypersensitive ALL patients exposed to Oncaspar, 11 patients were evaluated for response during induction. Of these, 3 patients (27%) achieved complete remission, 1 patient (9%) had partial remission, 1 patient (9%) had haematologic improvement and 2 patients (18%) had therapeutic efficacy. Therapeutic efficacy was defined as a clinical improvement which did not meet the criteria for other beneficial outcomes. During the maintenance phase, 19 patients were evaluated, with 17 patients (89%) achieving complete remission, and 1 patient (5%) with therapeutic efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Oncaspar pharmacokinetic properties were based on asparaginase activity measured by an enzymatic assay after intramuscular (CCG-1962) and intravenous (AALL07P4, DFCI 11-001) administration.</p><p>&nbsp;</p><p>In Study CCG-1962, mean asparaginase activity reached peak value of 1 U/mL on Day 5 after the injection. The mean half-life after absorption from the injection site was 1.7 days and the elimination half-life was 5.5 days. The volume of distribution at steady-state and clearance were estimated at</p><p>1.86 L/m2&nbsp;and 0.169 L/m2&nbsp;per day, respectively.</p><p>&nbsp;</p><p>In Study AALL07P4, PK parameters after a single 2,500 U/m2&nbsp;intravenous dose during Induction were calculated by noncompartmental PK analysis from sequential plasma samples and are depicted in Table&nbsp;3 (see section 5.1). The Cmax and AUC of Oncaspar trended lower in males, subjects with larger BMI, and subjects &gt;10 years. During Induction, following a single intravenous dose of Oncaspar 2,500 U/m2, asparaginase activity &ge;0.1 U/mL was sustained for up to 18 days post-dose in 95.3% of subjects.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table</strong><strong> &nbsp;3</strong>: &nbsp;<strong>Pharmacokinetic &nbsp;Parameters &nbsp;After &nbsp;a &nbsp;Single &nbsp;intravenous &nbsp;Dose &nbsp;of &nbsp;Oncaspar 2,500 U/m</strong><strong>2</strong><strong>&nbsp;</strong><strong>BSA During Induction (N=47; Study AALL07P4)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>PK Parameters</strong></p></td><td style="vertical-align:top"><p><strong>Arithmetic</strong><strong> </strong><strong>Mean (SD)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>C</strong><strong>max </strong><strong>(mU/mL)</strong>*</p></td><td style="vertical-align:top"><p>1638 (459.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>T</strong><strong>max </strong><strong>(hr)</strong>*</p></td><td style="vertical-align:top"><p>1.25 (1.08, 5.33)&dagger;</p></td></tr><tr><td style="vertical-align:top"><p><strong>AUC</strong><strong>0-t</strong><strong> </strong><strong>(mU</strong>ž<strong>day/mL)</strong>*</p></td><td style="vertical-align:top"><p>14810 (3555)</p></td></tr><tr><td style="vertical-align:top"><p><strong>AUC</strong><strong>0&ndash;</strong><strong>&yen;</strong><strong> </strong><strong>(mU</strong>ž<strong>day/mL)</strong>ǂ</p></td><td style="vertical-align:top"><p>16570 (4810)</p></td></tr><tr><td style="vertical-align:top"><p><strong>t</strong><strong>1/2 </strong><strong>(day)</strong>ǂ</p></td><td style="vertical-align:top"><p>5.33 (2.33)</p></td></tr><tr><td style="vertical-align:top"><p><strong>CL</strong><strong> </strong><strong>(L/day)</strong>ǂ</p></td><td style="vertical-align:top"><p>0.2152 (0.1214)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vss</strong><strong> (L)</strong>ǂ</p></td><td style="vertical-align:top"><p>1.95 (1.13)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* N=47 evaluable subjects.</p><p>&dagger; Median (10th, 90th percentiles).</p><p>ǂ N= 46 evaluable subjects.</p></td></tr></tbody></table><p>&nbsp;</p><p>In Study DFCI 11-001, assessments of asparaginase activity were performed following a single intravenous dose of Oncaspar 2,500 U/m2&nbsp;BSA during Induction, and every two weeks during post-Induction (see section 5.1). During Induction, plasma asparaginase activity &ge;0.1 U/mL was sustained in 93.5% of subjects 18 days after administration. During the post-Induction phase, a nadir (trough) asparaginase activity above 0.4 U/mL was sustained in 100% of subjects from Week 7 up until Week 25. These results indicate that, when Oncaspar 2,500 U/m2&nbsp;BSA is administered as single and repeated doses every two weeks, clinically relevant asparaginase activity is sustained over the entire dosing interval (i.e., two weeks).</p><p>&nbsp;</p><p>Patients with newly diagnosed ALL received a single intramuscular injection of Oncaspar (2,500 U/m&sup2; BSA) or native asparaginase from <em>E. coli </em>(25,000 U/m&sup2; BSA) or from <em>Erwinia </em>(25,000 U/m&sup2; BSA). The plasma elimination half-life of Oncaspar was statistically significantly longer (5.7 days) than the plasma &nbsp;elimination &nbsp;half-lives &nbsp;of &nbsp;the &nbsp;native &nbsp;asparaginases &nbsp;from &nbsp;<em>E. coli &nbsp;</em>(1.3 days) &nbsp;and &nbsp;<em>Erwinia</em></p><p>&nbsp;</p><p>(0.65 days). The immediate cell death of leukaemic cells <em>in vivo</em>, measured by rhodamine fluorescence, was the same for all three L-asparaginase preparations.</p><p>&nbsp;</p><p>ALL patients with several relapses were treated either with Oncaspar or with native asparaginase from</p><p><em>E. coli </em>as part of an induction therapy. Oncaspar was given intramuscular in a dose of 2,500 U/m&sup2; BSA on days 1 and 15 of induction. The mean plasma half-life of Oncaspar was 8 days in non-hypersensitive patients (AUC 10.35 U/ml/day), and 2.7 days in hypersensitive patients (AUC</p><p>3.52 U/ml/day).</p><p>&nbsp;</p><p><u>Specific populations</u></p><p>The controlled studies were not designed to formally evaluate the pharmacokinetics of Oncaspar in specific populations. A population pharmacokinetic evaluation of Oncaspar based on data obtained from Studies AALL07P4 (IV), DFCI 11-001 (IV), and CCG-1962 (IM) identified that clearance (linear and saturable) increased approximately proportionally to BSA and volume of distribution increased slightly more proportionally to BSA. No statistically significant differences in PK characteristics between male and female subjects were identified in this analysis.</p><p>&nbsp;</p><p>The impact of renal and hepatic impairment on the PK of Oncaspar has not been evaluated. As pegaspargase is a protein with a high molecular weight, it is not excreted renally, and no change of pharmacokinetic of Oncaspar in patients with renal impairment is foreseen.</p><p>&nbsp;</p><p>Since the proteolytic enzymes responsible for Oncaspar metabolism are ubiquitously distributed in tissues the exact role of the liver is unknown: however any decrease in liver function is not expected to present clinical relevant problems in the use of Oncaspar.</p><p>&nbsp;</p><p>There are no data available for elderly patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic/pharmacodynamic nonclinical comparability between the two pharmaceutical forms of Oncaspar, solution for injection/infusion, and powder for solution, was demonstrated in dogs after single and repeated doses (500 U/kg), by the intravenous route. The below mentioned studies were performed on the solution for injection/infusion formulation.</p><p>&nbsp;</p><p><u>Acute toxicity</u></p><p>Only very high doses of pegaspargase given to mice intraperitoneally as a single dose (25,000 &ndash; 100,000 U/kg body weight) caused the death of 14% of all treated mice. Mild hepatotoxicity was observed with the same doses. Adverse reactions were loss of body weight, piloerection and reduced activity. Reduced splenic weight might be a sign of potential immunosuppressant effect of the treatment.</p><p>&nbsp;</p><p>Pegaspargase was well tolerated both in rats and dogs when administered intravenously in single doses up to 500 U/kg body weight.</p><p>&nbsp;</p><p><u>Repeated dose toxicity</u></p><p>A 4-week study in rats treated with a dose of pegaspargase of 400 U/kg/day intraperitoneal resulted in a fall in food intake and body weight compared to the control group.</p><p>&nbsp;</p><p>A 3-month study in mice with pegaspargase at doses up to 500 U/kg intraperitoneally or intramuscularly resulted in slight hepatocellular changes only at the highest intraperitoneal dose.</p><p>&nbsp;</p><p>A temporary suppression in body weight gain and a temporary reduction in total leukocyte counts were observed in dogs which were treated with pegaspargase 1200 U/kg weekly for 2 weeks. Increased serum glutamic pyruvic transaminase activity also occurred in one out of four dogs.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>No immunogenic response was detected in a 12-week study in mice in which pegaspargase was administered weekly at the dose of 10.5 U/mouse intramuscularly or intraperitoneally.</p><p>&nbsp;</p><p><u>Reproductive toxicity</u></p><p>No studies of reproductive toxicity were conducted with pegaspargase.</p><p>&nbsp;</p><p>Embryotoxicity studies with L-asparaginase have showed evidence of teratogenic potential in rats treated from day 6 to 15 of gestation with a No Observed Effect Level (NOEL) for teratogenic effects at 300 U/kg intravenously. In rabbits, doses of 50 or 100 U/kg intravenous on days 8 and 9 of gestation induced viable fetuses with congenital malformations: no NOEL has been determined. Multiple malformations and embryolethal effects were observed with doses in the therapeutic range. Investigations of the effect on fertility and peri- and postnatal development were not conducted.</p><p>&nbsp;</p><p><u>Carcinogenicity, mutagenicity, fertility</u></p><p>Long-term investigations of carcinogenicity or studies of the effect on fertility in animals were not conducted with pegaspargase.</p><p>&nbsp;</p><p>Pegaspargase was not mutagenic in the Ames test using <em>Salmonella typhimurium </em>strains.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium phosphate heptahydrate</p><p>Sodium dihydrogen phosphate monohydrate Sodium chloride</p><p>Sucrose</p><p>Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial: 3 years.

Reconstituted solution
Chemical and physical in-use stability has been demonstrated for 24 hours below 25°C. From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

Diluted solution
Chemical and physical in-use stability has been demonstrated for 48 hours at 2°C-8°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C-8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C&ndash;8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I flint glass vial with chlorobutyl elastomer stopper, capped with a 20 mm aluminium flip-off seal, containing 3,750 U pegaspargase.</p><p>&nbsp;</p><p>Pack size of 1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product can cause irritation on contact. The powder must therefore be handled and administered with particular caution. Inhalation of the vapour and contact with the skin and mucous membranes, especially the eyes, must be avoided; if the medicinal product comes in contact with eyes, skin or mucous membranes, rinse immediately with plenty of water for at least 15 minutes.</p><p>&nbsp;</p><p>Oncaspar is to be administered intravenously or intramuscularly after reconstitution of the product. The powder must be reconstituted with 5.2 ml water for injections &nbsp;prior &nbsp;to &nbsp;administration &nbsp;(see section 4.2).</p><p>&nbsp;</p><p><u>Instructions for handling</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Staff should be trained in how to handle and transfer the medicinal product (pregnant staff should be excluded from working with this medicinal product).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aseptic technique must be used.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Procedures for proper handling of antineoplastic agents should be observed.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The &nbsp;use &nbsp;of &nbsp;disposable &nbsp;gloves &nbsp;and &nbsp;protective &nbsp;garments &nbsp;is &nbsp;recommended &nbsp;when &nbsp;handling Oncaspar.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All items for administration or cleaning, including gloves, should be placed in high-risk waste disposal bags for high-temperature incineration.</p><p>&nbsp;</p><p><u>Reconstitution</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.2 ml water for injections are injected into the vial using a syringe and 21 gauge needle.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The vial should be gently swirled until the powder is reconstituted.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After reconstitution, the solution should be clear, colourless and free from visible foreign particles. Do not use if the reconstituted solution is cloudy or if a precipitate has formed. Do not shake.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The solution should be used within 24 hours after reconstitution, when stored below 25&deg;C.</p><p>&nbsp;</p><p><u>Administration</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parenteral medicinal products should be inspected for particulate matter prior to administration, only a clear, colourless solution free from visible foreign particles should be used.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The medicinal product should be administered intravenously or intramuscularly. The solution should be administered slowly.</p><p>For intramuscular injection, the volume should not exceed 2 ml in children and adolescents and 3 ml in adults.</p><p>For intravenous administration, the reconstituted solution should be diluted in 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution.</p><p>The diluted solution can be given over 1 to 2 hours together with an already-running infusion of either sodium chloride 9 mg/ml or 5% glucose. Do not infuse other medicinal products through the same intravenous line during administration of Oncaspar (see section 4.2).</p><p>After dilution, the solution should be used immediately. If immediate use is not possible, the diluted solution can be stored at 2&deg;C-8&deg;C for up to 48 hours (see section 6.3).</p><p>&nbsp;</p><p><u>Disposal</u></p><p>Oncaspar is for single use only. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Les Laboratoires Servier 50, rue Carnot
92284 Suresnes cedex France


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>